

Prosensa, established in 2002, is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide.

In June 2013 Prosensa achieved a successful IPO on Nasdaq. Prosensa's lead product against DMD – Drisapersen – is in an approval process by the FDA (December 2014). In November 2014 BioMarin made a bid to acquire the company for \$680 million upfront and \$160 million in milestones.

## Prosensa

<b>Aktivität</b>	Treatment of neuromuscular diseases
<b>Land</b>	Niederlande
<b>Investitionsjahr</b>	2008
<b>Plattform</b>	Health & Care
<b>Website</b>	<a href="http://www.prosensa.eu">http://www.prosensa.eu</a>

